Boston scientific receives fda approval for expanded indication of ingevity™+ pacing leads to include conduction system pacing of the left bundle branch area

Marlborough, mass. , sept. 17, 2024 /prnewswire/ -- boston scientific corporation (nyse: bsx) has received u.s. food and drug administration (fda) approval to expand the indication for current-generation ingevity™+ pacing leads – thin wires placed inside the heart and connected to an implantable device – to include conduction system pacing (csp) and sensing of the left bundle branch area (lbba) when connected to a single- or dual-chamber pacemaker.
BSX Ratings Summary
BSX Quant Ranking